After the U.S. Court of Appeals for the Federal Circuit rejected Regeneron’s (REGN) request to temporarily block the launch during its appeal of a related decision for Amgen (AMGN) in a patent case in West Virginia, an Amgen spokesperson said the company will launch its biosimilar version of Regeneron’s blockbuster eye care drug Eylea, Reuters reported.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMGN:
- Regeneron price target lowered to $1,050 from $1,200 at Wells Fargo
- RBC would buy Regeneron on weakness with biosimilar Eylea priced in
- Morgan Stanley names Amgen ‘catalyst-driven idea’ into Phase 2 MariTide data
- Amgen price target raised to $383 from $381 at TD Cowen
- Uber downgraded, Zoom Video upgraded: Wall Street’s top analyst calls